Industry Roundup: Mannatech, FTC On Lunada, Nutroganics, Vitamin Shoppe
This article was originally published in The Tan Sheet
Mannatech rides Asia-Pacific growth; FTC disputes Lunada claims; Nutroganics sprouts profit; Vitamin Shoppe calms Oregon, Vermont on BMPEA; and more news in brief.
You may also be interested in...
Appropriations subcommittee largely ignores FDA; analysts predict lower Novartis OTC sales; France tightens advertising rules; NAD weighs in on Lunada claims; Global Biotechnologies supplements seized; Tetley tea faces lawsuit for antioxidant claims; more news In Brief.
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.